tbuckley/cabot-search huggingface dataset:
Diagnostic Test Accuracy of 18F-FDG PET or PET/CT in Merkel Cell Carcinoma
Authors: Sung Ryul Shim, Seong-Jang Kim
Journal: Clinical Nuclear Medicine (2022)

The purpose of the current study was to evaluate the diagnostic accuracies of 18 F-FDG PET or PET/CT for diagnosis of Merkel cell carcinoma (MCC) through a systematic review and meta-analysis.The PubMed, Cochrane database, and EMBASE database, from January 1990 to January 31, 2022, were searched for studies evaluating diagnostic performance of 18 F-FDG PET or PET/CT for MCC. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic curves.Across 9 studies (259 patients), the pooled sensitivity of 18 F-FDG PET or PET/CT was 0.91 (95% confidence interval [CI], 0.85-0.95) and a pooled specificity of 0.93 (95% CI, 0.86-0.97). Likelihood ratio syntheses gave an overall LR+ of 14.0 (95% CI, 6.6-29.6) and LR- of 0.09 (95% CI, 0.05-0.17). The pooled diagnostic odds ratio was 153 (95% CI, 57-416).18 F-FDG PET/CT showed an excellent performance for diagnosis of MCC. The likelihood ratio scattergram indicated that 18 F-FDG PET or PET/CT is useful for exclusion and confirmation of MCC. Further large multicenter studies would be necessary to substantiate the diagnostic accuracy of 18 F-FDG PET or PET/CT for MCC patients.
SO-28 Gut microbiome characterization and correlation with colonoscopy findings in oncological and non-oncological patients from a Chilean cancer center
Authors: R. Gonzalez-Stegmaier, R. Jorquera, T. Ejsmentewicz, S. Gonzalez, R. Lagos, C. Podesta, M. Garcia, C. Barrientos, F. Villarroel-Espindola
Journal: Annals of Oncology (2022)
P-39 Utility of circulating tumor DNA (ctDNA) to assess tumor response in patients with locally advanced rectal cancer undergoing neoadjuvant therapy
Authors: S. Chakrabarti, R. Benrud, J. Chau, W. Hall, A. Shreenivas, B. Erickson, C. Peterson, T. Ridolfi, J. Miller, A. Banerjee, J. Thomas, S. Sharif, N. Fei, K. Ludwig, P. Olshan, C. Palsuledesai, M. Malhotra, A. Jurdi, A. Aleshin, P. Kasi
Journal: Annals of Oncology (2022)
P-196 Circulating tumor DNA as a prognostic biomarker in pancreatic cancer patients treated with FOLFIRINOX: A prospective cohort study
Authors: J. Chun, N. Han, M. Kim, D. Lee, H. Park, S. Han, S. Park, T. Kim, W. Lee, Y. Kim, S. Kong, S. Woo
Journal: Annals of Oncology (2022)
P-81 Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1–positive metastatic colorectal cancer (mCRC)
Authors: T. Kim, J. Taieb, M. Passhak, T. Kim, S. Kim, R. Geva, E. Hofsli, G. Perl, S. Yalcin, A. Hubert, B. Somer, Z. Wong, A. Wang, P. Leconte, D. Fogelman, V. Heinemann
Journal: Annals of Oncology (2022)
Hospitalization Patterns and Impact of a Magnetically-Levitated Left Ventricular Assist Device in the MOMENTUM 3 Trial
Authors: Himabindu Vidula, Koji Takeda, Jerry D. Estep, Scott C. Silvestry, Carmelo Milano, Joseph C. Cleveland, Daniel J. Goldstein, Nir Uriel, Robert L. Kormos, Nicholas Dirckx, Mandeep R. Mehra
Journal: JACC Heart Failure (2022)

In the MOMENTUM 3 (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3) pivotal trial, the HeartMate 3 (HM3) fully magnetically levitated left ventricular assist device (LVAD) demonstrated superiority over the axial-flow HeartMate II (HMII) LVAD. The patterns and predictors of hospitalizations with the HM3 LVAD have not been characterized. This study sought to determine causes, predictors, and impact of hospitalizations during LVAD support. Patients discharged after LVAD implantation were analyzed. In the pivotal trial, 485 recipients of HM3 were compared with 471 recipients of HMII. The pivotal trial HM3 group was also compared to 949 recipients of HM3 in the postapproval phase within the trial portfolio. Predictors of cause-specific rehospitalization were analyzed. The rates of rehospitalization were lower with HM3 LVAD than with HMII LVAD in the pivotal trial (225.7 vs 246.4 events per 100 patient-years; P < 0.05). Overall, rehospitalization rates and duration were similar in the HM3 postapproval phase and pivotal trial but prolonged hospitalizations (>7 days) were less frequent (rate ratio: 0.90 [95% CI: 0.80-0.98]; P < 0.05). In HM3 recipients, the most frequent causes of rehospitalization included infection, heart failure (HF)-related events, and bleeding. First rehospitalization caused by HF-related event versus other causes was associated with reduced survival (HR: 2.2 [95% CI: 1.3-3.9]; P = 0.0014). Male sex, non-White race, presence of cardiac resynchronization therapy/implantable cardioverter-defibrillator, obesity, higher right atrial pressure, smaller LV size, longer duration of index hospitalization, and lower estimated glomerular filtration rate at index discharge predicted HF hospitalizations. Contemporary support with the HM3 fully magnetically levitated LVAD is associated with a lower hospitalization burden than with prior pumps; however, rehospitalizations for infection, HF, and bleeding remain important challenges for progress in the patient journey. (MOMENTUM 3 IDE Clinical Study, NCT02224755; MOMENTUM 3 Continued Access Protocol [MOMENTUM 3 CAP], NCT02892955)
Correction: Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling
Authors: Tao Wang, Wen Song, Yuan Chen, Ruibao Chen, Zhuo Liu, Licheng Wu, Mingchao Li, Jun Yang, Liang Wang, Jihong Liu, Zhangqun Ye, Chenguang Wang, Ke Chen
Journal: Clinical Cancer Research (2022)

In the original version of this article (1), Supplementary Fig. S6D contained the experimental pictures for LNCaP instead of C4-2. The figure file has been replaced with a corrected version in the latest online HTML of the article. The authors regret the error.
P-210 Germline testing in pancreatic adenocarcinoma
Authors: E. Terán Brage, E. Sánchez Tapia, R. Vidal Tocino, J. Pérez García, Á. López Gutiérrez, M. Navarro Martín, T. Martín Gómez, R. González Sarmiento, R. Seijas Tamayo, J. Cruz Hernández, E. Fonseca Sánchez
Journal: Annals of Oncology (2022)
Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis
Authors: Ayobami Akenroye, Grace Lassiter, John W. Jackson, Corinne Keet, Jodi Segal, G. Caleb Alexander, Hwanhee Hong
Journal: Journal of Allergy and Clinical Immunology (2022)

The comparative safety and efficacy of the biologics currently approved for asthma are unclear.
Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation
Authors: Sarah Diver, Koirobi Haldar, Pamela Jane McDowell, John Busby, Vijay Mistry, Claudia Micieli, Vanessa Brown, Ciara Cox, Freda Yang, Catherine Borg, Rahul Shrimanker, Mohammadali Yavari Ramsheh, Tim Hardman, Joseph Arron, Peter Bradding, Douglas Cowan, Adel Hasan Mansur, Stephen J. Fowler, Jim Lordan, Andrew Menzies‐Gow, Douglas Robinson, John Matthews, Ian D. Pavord, Rekha Chaudhuri, Liam G. Heaney, Michael R. Barer, Christopher Brightling
Journal: Allergy (2022)

In T2-mediated severe asthma, biologic therapies, such as mepolizumab, are increasingly used to control disease. Current biomarkers can indicate adequate suppression of T2 inflammation, but it is unclear whether they provide information about airway microbial composition. We investigated the relationships between current T2 biomarkers and microbial profiles, characteristics associated with a ProteobacteriaHIGH microbial profile and the effects of mepolizumab on airway ecology.Microbiota sequencing was performed on sputum samples obtained at stable and exacerbation state from 140 subjects with severe asthma participating in two clinical trials. Inflammatory subgroups were compared on the basis of biomarkers, including FeNO and sputum and blood eosinophils. ProteobacteriaHIGH subjects were identified by Proteobacteria to Firmicutes ratio ≥0.485. Where paired sputum from stable visits was available, we compared microbial composition at baseline and following ≥12 weeks of mepolizumab.Microbial composition was not related to inflammatory subgroup based on sputum or blood eosinophils. FeNO ≥50 ppb when stable and at exacerbation indicated a group with less dispersed microbial profiles characterised by high alpha-diversity and low Proteobacteria. ProteobacteriaHIGH subjects were neutrophilic and had a longer time from asthma diagnosis than ProteobacteriaLOW subjects. In those studied, mepolizumab did not alter airway bacterial load or lead to increased Proteobacteria.High FeNO could indicate a subgroup of severe asthma less likely to benefit from antimicrobial strategies at exacerbation or in the context of poor control. Where FeNO is <50 ppb, biomarkers of microbial composition are required to identify those likely to respond to microbiome-directed strategies. We found no evidence that mepolizumab alters airway microbial composition.
SO-3 Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma
Authors: M. Rimini, T. Macarulla, V. Burgio, S. Lonardi, M. Niger, M. Scartozzi, I. Rapposelli, G. Aprile, F. Ratti, F. Pedica, F. Nappo, C. Fabregat, M. Fassan, G. Frassineti, F. Simionato, F. De Cobelli, L. Aldrighetti, L. Fornaro, S. Cascinu, A. Casadei Gardini
Journal: Annals of Oncology (2022)
P-63 Efficacy, safety and prognostic subgroups for outcome with regorafenib in patients with refractory metastatic colorectal cancer in the real-world setting: The CORE study
Authors: N. Martínez-Lago, B. Carnero Lopez, J. de la Cámara Gómez, F. Vázquez-Rivera, A. Fernández Montes, A. Cousillas Castiñeiras, N. de Dios, R. Varela Ponte, M. Reboredo-Lopez
Journal: Annals of Oncology (2022)
SO-37 Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib + cetuximab ± binimetinib: Subanalysis of BEACON CRC
Authors: K. Ng, F. Ciardiello, E. Van Cutsem, R. Yaeger, T. Yoshino, J. Desai, H. Wasan, B. Alkuzweny, X. Zhang, J. Tabernero, S. Kopetz
Journal: Annals of Oncology (2022)
Adverse roles of mast cell chymase-1 in COPD
Authors: Gang Liu, Andrew G. Jarnicki, Keshav R. Paudel, Wenying Lu, Ridhima Wadhwa, Ashleigh M. Philp, Hannelore Van Eeckhoutte, Jacqueline E. Marshall, Vamshikrishna Malyla, Angelica Katsifis, Michael Fricker, Nicole G. Hansbro, Kamal Dua, Nazanin Z. Kermani, Mathew S. Eapen, Angelica Tiotiu, K. Fan Chung, Gaetano Caramori, Ken Bracke, Ian M. Adcock, Sukhwinder S. Sohal, Peter A. Wark, Brian G. Oliver, Philip M. Hansbro
Journal: European Respiratory Journal (2022)

Background COPD is the third leading cause of death worldwide. Cigarette smoke (CS)-induced chronic inflammation inducing airway remodelling, emphysema and impaired lung function is the primary cause. Effective therapies are urgently needed. Human chymase (hCMA)1 and its orthologue mCMA1/mouse mast cell protease (mMCP)5 are exocytosed from activated mast cells and have adverse roles in numerous disorders, but their role in COPD is unknown. Methods We evaluated hCMA1 levels in lung tissues of COPD patients. We used mmcp5 -deficient ( −/− ) mice to evaluate this protease's role and potential for therapeutic targeting in CS-induced experimental COPD. In addition, we used ex vivo/in vitro studies to define mechanisms. Results The levels of hCMA1 mRNA and CMA1 + mast cells were increased in lung tissues from severe compared to early/mild COPD patients, non-COPD smokers and healthy controls. Degranulated mast cell numbers and mMCP5 protein were increased in lung tissues of wild-type mice with experimental COPD. mmcp5 −/− mice were protected against CS-induced inflammation and macrophage accumulation, airway remodelling, emphysema and impaired lung function in experimental COPD. CS extract challenge of co-cultures of mast cells from wild-type, but not mmcp5 −/− mice with wild-type lung macrophages increased in tumour necrosis factor (TNF)-α release. It also caused the release of CMA1 from human mast cells, and recombinant hCMA-1 induced TNF-α release from human macrophages. Treatment with CMA1 inhibitor potently suppressed these hallmark features of experimental COPD. Conclusion CMA1/mMCP5 promotes the pathogenesis of COPD, in part, by inducing TNF-α expression and release from lung macrophages. Inhibiting hCMA1 may be a novel treatment for COPD.
Malignant duodenocolic fistula successfully treated with self-expandable partially covered metal stent and endoscopic suturing
Authors: Marco Sacco, Marcantonio Gesualdo, Federica Fimiano, Anna Mauriello, Fabio Castellano, Stefania Caronna, Claudio De Angelis
Journal: Endoscopy (2022)

Duodenocolic fistula is a rare complication of right-sided colon cancer and its management can be challenging because of surgery-related morbidity, especially in fragile patients in a palliative care setting [1]. Endoscopic treatment with self-expandable metal stents (SEMSs) is still a feasible and safe option in patients with poor performance status, but the risk of stent migration is not negligible [2].
P-261 Epidemiological evolution of colorectal cancer over 10 years: Incidence, mortality and survival: Experience of the medical oncology department of Fez
Authors: S. El Anssari, Z. Benbrahim, Y. Elhaitmy, I. Elbadisy, F. Abbass, L. Amaadour, K. Oualla, S. Arifi, K. Elghazi, M. Nawfel
Journal: Annals of Oncology (2022)
SO-40 Measurement of circulating tumor DNA (ctDNA) in appendiceal adenocarcinoma (AA): Prevalence, predictors, and correlation with clinical outcome
Authors: M.A. Zeineddine, F.A. Zeineddine, A. Yousef, M. Overman, M. White, A. Uppal, T. Newhook, A. Dasari, K. Fournier, K. Raghav, J. Shen
Journal: Annals of Oncology (2022)
The alarmin(g) effect of interleukin-5 blockade on residual eosinophil function is of clinical consequence
Authors: Simon Couillard
Journal: European Respiratory Journal (2022)

<b>Van Hulst and co-workers report stronger SOCS3 induction in blood eosinophils from mepolizumab-treated patients stimulated <i>ex vivo</i> with IL-33. The clinical significance is yet unknown, but it may explain some eosinophilic asthma attacks under mepolizumab.</b>https://bit.ly/3yqp4If
O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202
Authors: A. Vogel, V. Sahai, A. Hollebecque, G. Vaccaro, D. Melisi, R. Al-Rajabi, S. Paulson, M. Borad, D. Gallinson, A. Murphy, D. Oh, E. Dotan, D. Catenacci, E. Van Cutsem, C. Lihou, H. Zhen, L. Veronese, G. Abou-Alfa
Journal: Annals of Oncology (2022)
P-8 Long-term survival in patients with pancreatic cancer (PAC) treated with liposomal irinotecan in combination with 5-fluorouracil and leucovorin (nal-IRI+5-FU/LV)
Authors: G. Prager, K. Potthoff, C. Yoo, S. Lonardi, F. Hédouin-Biville, T. Macarulla
Journal: Annals of Oncology (2022)
P-191 Ampullary neoplasms – how to treat in real-world practice? A retrospective study
Authors: M. Sardinha, D. Simão, L. Gil, A. Spencer, A. Reis, J. Leão, A. Montenegro, R. Ferreira, I. Furtado, F. Verdasca, R. Escaleira, M. Miguens, P. Winckler, R. Luz
Journal: Annals of Oncology (2022)
LBA SO-23 Real-world evaluation of clinical utility of ColonAiQ, a blood-based assay for colorectal cancer (CRC) early detection
Authors: Y. Ding, J. Liu, R. Liu, Y. Zhang, Y. Li, F. Li, C. Wang, H. Jia, W. Pan, H. Yang, H. Luo, Y. Li
Journal: Annals of Oncology (2022)
P-89 Real-world utility of full staging with 18-fluorodeoxyglucose positron emission tomography (18FDG-PET) in addition to standard imaging in patients with non-metastatic non-resectable pancreatic ductal adenocarcinoma (PDAC)
Authors: R. Wheatley, M. McNamara, J. Gleeson, R. Hubner, P. Manoharan, J. Valle, A. Lamarca
Journal: Annals of Oncology (2022)
SO-25 Total neoadjuvant therapy (TNT) in early-onset (EO) vs average-onset (AO) locally advanced rectal cancer (LARC): Patient characteristics and tolerance
Authors: M. Conces, E. Gorgun, N. Tursun, I. Ozgur, D. Elamin, S. Yilmaz, S. Patil, D. Liska, S. Kamath, S. Steele, A. Khorana, B. Laderian, K. Nair, S. Amarnath, B. Estfan, M. Shapiro, M. McNamara, M. Valente, H. Kessler, S. Krishnamurthi
Journal: Annals of Oncology (2022)
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age
Authors: Michael Böhm, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Amr Abdin, Felix Mahfoud, Martina Brueckmann, Nicholas D. Gollop, Tomoko Iwata, Piotr Ponikowski, Christoph Wanner, Faiez Zannad, Milton Packer, Stefan D. Anker
Journal: Journal of the American College of Cardiology (2022)

Empagliflozin reduces cardiovascular death (CVD) or heart failure (HF) hospitalization (HFH) in patients with HF and preserved ejection fraction. Treatment effects and safety in relation to age have not been studied.The purpose of this study was to evaluate the interplay of age and empagliflozin effects in EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction).We grouped patients (n = 5,988) according to their baseline age (<65 years [n = 1,199], 65-74 years [n = 2,214], 75-79 years [n = 1,276], ≥80 years [n = 1,299]). We explored the influence of age on empagliflozin effects on CVD or HFH (primary outcome), total HFH, rate of decline in estimated glomerular filtration rate, health-related quality of life with the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score, and frequency of adverse events.Considering only patients on placebo, the incidence of primary outcomes (P trend = 0.02) and CVD (P trend = 0.003) increased with age. Empagliflozin reduced primary outcomes (P trend = 0.33), first HFH (P trend = 0.22), and first and recurrent HFH (P trend = 0.11) across all age groups with an effect being similar at ≥75 years (P interaction = 0.22) or >80 years (P interaction = 0.51). Empagliflozin improved Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score at week 52 and attenuated the decline of estimated glomerular filtration rate without age interaction (P = 0.48 and P = 0.32, respectively). There were no clinically relevant differences in adverse events between empagliflozin and placebo across the age groups.Empagliflozin reduced primary outcomes and first and recurrent HFH and improved symptoms across a broad age spectrum. High age was not associated with reduced efficacy or meaningful intolerability. (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction [EMPEROR-Preserved]; NCT0305951).
P-111 Increased risk of pancreatic cancer among 141,387 diabetic patients treated with DPP-4 inhibitors analyzed with common data model
Authors: J. Lee, D. Kang, I. Choi, D. Jang
Journal: Annals of Oncology (2022)

DPP-4i are incretin-based anti-diabetes drugs which have been introduced recently. It is concerned that, however, that DPP-4i might cause pancreatic cancer or pancreatitis due to the pleiotropic effects for the exocrine pancreas. In this study, the association between pancreatic cancer and DPP-4i was investigated based on CDM, an emerging tool for real world data (RWD) analysis. The electronic hospital record (EHR) of diabetic patients treated with Dipeptidyl peptidase 4 inhibitors (DPP-4i) from 2006 to 2019 was pooled into common data model (CDM) and compared with those with sodium-glucose cotransporter inhibitors (SGLT)-2i as the control. The enrollment assessment window was considered 6 months. The blackout and washout periods were defined as 2 and 56 days, respectively. Each cohort of DPP-4i and SGLT-2i consisting of 141,387 and 13,378 patients was formed. Pancreatic cancer was identified in 2,803 (2.14%) patients from the DPP-4i cohort and 129 (1.07%) from the SGLT-2i cohort, which showed statistical difference (P < 0.0001). The odds ratio was 2.02 (95% confidential interval: 1.69-2.41) with fixed and random effect models. The study suggests there is increased risk of pancreatic cancer for patients treated with DPP-4i.
A rare case of a windsock-shaped intraluminal duodenal diverticulum treated successfully with endoscopic diverticulectomy
Authors: Bülent Ödemiş, Batuhan Başpınar, Çağdaş Erdoğan, Deniz Ogutmen Koc, Banu Demet Özel Coşkun, Serkan Torun
Journal: Endoscopy (2022)

An intraluminal duodenal diverticulum is a rare congenital anomaly stemming from incomplete duodenal lumen formation during embryogenesis [1] [2] [3] [4] [5]. Over time, the remnant duodenal diaphragm resembles a windsock by elongation secondary to intestinal peristaltic movements [1] [2] [3]. In most patients, the condition is detected incidentally [1] [2]. However, a few patients may present in adulthood with symptoms of partial duodenal obstruction, such as early satiety, vomiting, and abdominal pain [1] [2]. Rare bleeding and pancreatitis may complicate the scenario [1] [2]. Herein we present a case treated with endoscopic intraluminal diverticulectomy ([Fig. 1]).
ALK1 controls hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic telangiectasia of the liver
Authors: Christian David Schmid, Victor Olsavszky, Manuel Reinhart, Vanessa Weyer, Felix A. Trogisch, Carsten Sticht, Manuel Winkler, Sina W. Kürschner, Johannes Hoffmann, Roxana Ola, Theresa Staniczek, Joerg Heineke, Beate K. Straub, Jens Mittler, Kai Schledzewski, Peter ten Dijke, Karsten Richter, Steven Dooley, Cyrill Géraud, Sergij Goerdt, Philipp‐Sebastian Koch
Journal: Hepatology (2022)

Background and Aims: In hereditary hemorrhagic telangiectasia (HHT), severe liver vascular malformations are associated with mutations in the Activin A Receptor‐Like Type 1 ( ACVRL1 ) gene encoding ALK1, the receptor for bone morphogenetic protein (BMP) 9/BMP10, which regulates blood vessel development. Here, we established an HHT mouse model with exclusive liver involvement and adequate life expectancy to investigate ALK1 signaling in liver vessel formation and metabolic function. Approach and Results: Liver sinusoidal endothelial cell (LSEC)‐selective Cre deleter line, Stab2‐iCreF3 , was crossed with Acvrl1 ‐floxed mice to generate LSEC‐specific Acvrl1 ‐deficient mice ( Alk1 HEC‐KO ). Alk1 HEC‐KO mice revealed hepatic vascular malformations and increased posthepatic flow, causing right ventricular volume overload. Transcriptomic analyses demonstrated induction of proangiogenic/tip cell gene sets and arterialization of hepatic vessels at the expense of LSEC and central venous identities. Loss of LSEC angiokines Wnt2 , Wnt9b , and R‐spondin‐3 ( Rspo3 ) led to disruption of metabolic liver zonation in Alk1 HEC‐KO mice and in liver specimens of patients with HHT. Furthermore, prion‐like protein doppel ( Prnd ) and placental growth factor ( Pgf ) were upregulated in Alk1 HEC‐KO hepatic endothelial cells, representing candidates driving the organ‐specific pathogenesis of HHT. In LSEC in vitro , stimulation or inhibition of ALK1 signaling counter‐regulated Inhibitors of DNA binding (ID)1–3, known Alk1 transcriptional targets. Stimulation of ALK1 signaling and inhibition of ID1–3 function confirmed regulation of Wnt2 and Rspo3 by the BMP9/ALK1/ID axis. Conclusions: Hepatic endothelial ALK1 signaling protects from development of vascular malformations preserving organ‐specific endothelial differentiation and angiocrine signaling. The long‐term surviving Alk1 HEC‐KO HHT model offers opportunities to develop targeted therapies for this severe disease.
P-86 First-line nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 2-year follow-up
Authors: L. Shen, Y. Bai, X. Lin, W. Li, J. Wang, X. Zhang, H. Pan, C. Bai, L. Bai, Y. Cheng, J. Zhang, H. Zhong, Y. Ba, W. Hu, R. Xu, W. Guo, S. Qin, N. Yang, J. Lu, C. Amaya Chanaga, S. Soleymani, T. Liu
Journal: Annals of Oncology (2022)